Health Care & Life Sciences » Healthcare Provision | Shin Nippon Biomedical Laboratories Ltd.

Shin Nippon Biomedical Laboratories Ltd. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Sales/Revenue
16,926
17,835
14,750
17,244
16,601
15,659
Cost of Goods Sold (COGS) incl. D&A
11,454
12,153
12,303
13,136
11,451
9,694
Gross Income
5,473
5,682
2,447
4,109
5,150
5,964
SG&A Expense
6,196
6,318
6,384
5,901
5,847
5,205
EBIT
724
636
3,863
1,793
697
760
Unusual Expense
254
580
6,921
772
282
311
Non Operating Income/Expense
1,049
1,426
1,793
607
801
1,199
Interest Expense
307
290
304
378
374
378
Pretax Income
96
399
3,550
765
1,508
1,651
Income Tax
858
992
903
128
2,013
308
Consolidated Net Income
762
1,391
2,647
892
3,521
1,959
Net Income
755
1,386
2,646
916
3,556
1,950
Net Income After Extraordinaries
755
1,386
2,646
916
3,556
1,950
Net Income Available to Common
755
1,386
2,646
916
3,556
1,950
EPS (Basic)
20.11
34.84
66.53
22.18
85.41
46.85
Basic Shares Outstanding
38
40
40
41
42
42
EPS (Diluted)
20.12
34.84
66.53
22.18
85.41
46.85
Diluted Shares Outstanding
38
40
40
41
42
42
EBITDA
595
756
2,271
247
775
2,121
Other Operating Expense
-
-
73
-
-
-
Non-Operating Interest Income
8
4
15
15
9
19
Minority Interest Expense
7
5
1
23
35
8
Equity in Affiliates (Pretax)
185
322
1,011
12
638
362

About Shin Nippon Biomedical Laboratories

View Profile
Address
St. Luke's Tower, 12/F
Tokyo Tokyo 104
Japan
Employees -
Website http://www.snbl.co.jp
Updated 07/08/2019
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: Preclinical Business, Clinical Business, Translational Research Business, Medipolis Business, and Others. The Preclinical Business segment verifies the efficacy and safety of new drugs using experimental animals and bacterial cells.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.